LKB1 suppresses growth and promotes the internalization of EGFR through the PIKFYVE lipid kinase

  • bioRxiv. 2023 Oct 20:2023.10.19.563158. doi: 10.1101/2023.10.19.563158.
John R Ferrarone ,  Jerin Thomas ,  Arun M Unni ,  Yuxiang Zheng ,  Michal J Nagiec ,  Eric E Gardner ,  Oksana Mashadova ,  Kate Li ,  Nikos Koundouros ,  Antonino Montalbano ,  Meer Mustafa ,  Lewis C Cantley ,  John Blenis ,  Neville E Sanjana ,  Harold Varmus
Abstract

The tumor suppressor LKB1 is a serine/threonine protein kinase that is frequently mutated in human Lung Adenocarcinoma (LUAD). LKB1 regulates a complex signaling network that is known to control cell polarity and metabolism; however, the pathways that mediate the tumor suppressive activity of LKB1 are incompletely defined. To identify mechanisms of LKB1- mediated growth suppression we developed a spheroid-based Cell Culture assay to study LKB1- dependent growth. Using this assay, along with genome-wide CRISPR screens and validation with orthogonal methods, we discovered that LKB1 suppresses growth, in part, by activating the PIKFYVE Lipid Kinase, which promotes the internalization of wild-type EGFR. Our findings reveal a new mechanism of regulation of EGFR, which may have implications for the treatment of LKB1 -mutant LUAD.

Products